MAPT and myeloid sarcoma: The impact of SVF therapy can be measured using disease‐specific clinical metrics such as the expanded disability status scale (EDSS) for MS or the Movement Disorder Society Unified Disease Rating Scale (MDS‐UPDRS) for PD, or tracking of tau or amyloid through positron emission tomography (PET) for AD.88